Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

Journal of Medical Virology

Volumn 81, Issue 6, 2009, Pages 1032-1039

  Akuta, Norio ^a   Suzuki, Fumitaka ^a   Hirakawa, Miharu ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Cirrhosis; Core region; Diabetes mellitus; Genotype; HCV; Hepatocyte steatosis; HOMA IR

Indexed keywords

GLUTAMINE; HISTIDINE; METHIONINE; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; CORE PROTEIN; INTERFERON; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CLINICAL EVALUATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GENOTYPE; GROUPS BY AGE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; JAPANESE; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PROTEIN STRUCTURE; STEATOSIS; TREATMENT DURATION; GENETICS; JAPAN; MIDDLE AGED; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN RESISTANCE; INTERFERONS; JAPAN; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME; VIRAL CORE PROTEINS; YOUNG ADULT;

EID: 66449096358     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21473     Document Type: Article

References (51)

1. Akuta N, Chayama K, Suzuki F, Someya T, Kobayashi M, Tsubota A, SuzukiY, Saitoh S, Arase Y, IkedaK, Kumada H. 2001. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 allele. J Med Virol 64:109-116. (Pubitemid 32405398)
2. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayshi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48:372-380. (Pubitemid 41003622)
3. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2006. Predictive factors of virological nonresponse to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 78:83-90. (Pubitemid 41783847)
4. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007a. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 46:403-410. (Pubitemid 46185701)
5. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007b. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79:1686-1695. (Pubitemid 47479887)
6. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, KobayashiM, AraseY, Ikeda K,Miyakawa Y, Kumada H. 2007c. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 50:361-368.
7. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007d. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46:1357-1364.
8. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2008. Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alphafetoprotein in patients without hepatocellular carcinoma. J Med Virol 80:1354-1362.
9. Allison ME,Wreghitt T, Palmer CR, Alexander GJ. 1994.Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21:1135-1139.
10. American Diabetes Association. 2000. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 23:S4-S19.
11. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E. 2005. Hepatitis C virus infection: Evidence for an association with type 2 diabetes. Diabetes Care 28:2548-2550. (Pubitemid 41384312)
12. Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. 2009. Endocrine manifestations of hepatitis C virus infection. Nat Clin Pract Endocrinol Metab 5:26-34.
13. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. 2008. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology (in press).
14. Cammà C, Bruno S, Di Marco V, Di Bona D, Rumi M, VinciM, Rebucci C, Cividini A, Pizzolanti G, Minola E, Mondelli MU, Colombo M, Pinzello G, Craxì A. 2006. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43:64-71. (Pubitemid 43738959)
15. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O'Rahilly S, Shore S, Tom BD, Alexander GJ. 1999. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30:1059-1063. (Pubitemid 29458297)
16. Chayama K, TsubotaA,Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, Kobayashi M, Iwasaki S, Koyama S, Morinaga T, Kumada H. 1993. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 8:150-156. (Pubitemid 23085546)
17. Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, Lu RH, Yu MI, Chang CY, Yang PL, Lee CY, Chang FY. 2008. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 29:46-54.
18. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Virahep-C StudyGroup. 2007. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45:80-87. (Pubitemid 46144367)
19. Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ. 1994. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520. (Pubitemid 24166476)
20. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, Belle SH, Di Bisceglie AM, Aurora R, Tavis JE. 2007. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81:8211-8224. (Pubitemid 47101507)
21. D'Souza R, Sabin CA, Foster GR. 2005. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 100:1509-1515. (Pubitemid 41032355)
22. Dusheiko GM. 1998. The natural course of chronic hepatitis C: Implications for clinical practice. J Viral Hepatol Suppl 1:9-12. (Pubitemid 28448910)
23. El-Serag HB, Richardson PA, Everhart JE. 2001. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. Am J Gastroenterol 96:2462-2467. (Pubitemid 32769212)
24. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. 1995. Comparison of full-length sequences of interferon sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96:224-230.
25. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77-81. (Pubitemid 26017933)
26. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. 2005. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54:1003-1008. (Pubitemid 40873917)
27. Georgescu EF, Lonescu R, Florescu G, Mateescu G, Vancica L. 2008. Steatosis, insulin resistance, iron overload, fibrosis and viral load as negative factors affecting early (EVR) and sustained (SVR) virological response in patients with chronic hepatitis C treated with peginterferon and ribavirin. Hepatology 48:A869.
28. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. 2003. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: Implications for therapy. J Hepatol 39:1042-1048.
29. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. 2003. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125:1695-1704. (Pubitemid 37500434)
30. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I,Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H. 1998. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. J Hepatol 28:930-938. (Pubitemid 28275969)
31. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, Shimotono K. 1990. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528. (Pubitemid 120016475)
32. Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. 2007. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102:570-576. (Pubitemid 46328143)
33. Kenny-Walsh E. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340:1228-1233. (Pubitemid 29407381)
34. Lai MS, Hsieh MS, Chiu YH, Chen TH. 2006. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295-1302. (Pubitemid 43980108)
35. Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. 2004. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care 27:1171-1175. (Pubitemid 38579785)
36. Lecube A, Hernández C, Genescà J, Simó R. 2006. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 29:1096-1101. (Pubitemid 44115250)
37. Mason AL, Lau JY, Hoang N,Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333. (Pubitemid 29088433)
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419. (Pubitemid 15018832)
39. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. 2000. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592-599.
40. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, NetskiD, Coresh J, Szklo M, Thomas DL. 2003. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 38:50-56. (Pubitemid 36775795)
41. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. 1998. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065-1067. (Pubitemid 28417341)
42. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. 2008. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 134:416-423.
43. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L, Hensel F, Petry W, Häussinger D. 1998. Progress of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 28:1687-1695. (Pubitemid 28549142)
44. Okanoue T, Itoh Y, Yotsuyanagi H, Tanaka E, Yoshioka K, Izumi N, Kumada H. 2008. Substitution of core amino acid 91 lowers rapid virological response and substitution of core amino 70 lowers sustained virological response to peginterferon alfa-2b plus ribavirin in chronic hepatitis C patients with genotype 1b-nationwide study. Hepatology 48:868A.
45. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. 1994. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 19:616-627. (Pubitemid 24066891)
46. Petta S, Cammà C, Marco VD, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A. 2008. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103:1136-1144.
47. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. 2005. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641. (Pubitemid 40585366)
48. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K. 2004. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology 126:840-848. (Pubitemid 38298332)
49. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. 2008. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856-1862.
50. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. 2000. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol 32:209-217. (Pubitemid 30093899)
51. Zein CO, Levy C, Basu A, Zein NN. 2005. Chronic hepatitis C and type II diabetes mellitus: A prospective cross-sectional study. Am J Gastroenterol 100:48-55. (Pubitemid 41623268)